Market Access Blogs December 19, 2024 The Future of 340B and Independent Pharmacies in a Post-IRA World 5 Minute Read Efficient inventory management is crucial for healthcare organizations to ensure patient satisfaction, maintain financial stability, and mitigate supply chain risks. Moving forward, drug manufacturers must adapt their inventory management...
Corporate December 10, 2024 Expansion of Data Quality Monitoring and Inventory Roll Forward 2 Minute Read Efficient inventory management is crucial for healthcare organizations to ensure patient satisfaction, maintain financial stability, and mitigate supply chain risks. Moving forward, drug manufacturers must adapt their inventory management...
Contracts & Pricing December 10, 2024 Navigating DSCSA Compliance: Overcoming Challenges in the Pharmaceutical Supply Chain 4 Minute Read As the industry approaches full compliance with DSCSA requirements, new challenges emerge, particularly in managing data discrepancies, addressing inventory exceptions, and navigating gross-to-net impacts.
Government Pricing December 10, 2024 New Government Pricing Tools: Unraveling the Complexities of Government Pricing 2 Minute Read The pharmaceutical industry faces increasing difficulty accurately calculating and reporting government prices due to stringent regulations and recent complex changes.
Corporate November 4, 2024 Why I Chose IntegriChain: A Journey from Tech Giants to Transforming... 3 Minute Read Read the latest blog from our CCO Tim Murdoch, Why I Chose IntegriChain: A Journey from Tech Giants to Transforming Pharma Commercialization.
Contracts & Pricing October 31, 2024 Industry Shifts: A Closer Look at Recent CMS and J&J Announcements 3 Minute Read Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
Contracts & Pricing September 4, 2024 $35 Patient Out-of-Pocket Strategy: Impacts on Prescription Drug Affordability & Implications... 3 Minute Read Katie Herrick and Dan Landis, consultants from Blue Fin Group, discuss how pharmaceutical companies are adapting to the changing healthcare environment by focusing on improving patient access and affordability.
Contracts & Pricing September 4, 2024 Key Developments in Pharmaceutical Pricing Regulations 4 Minute Read Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
Market Access Blogs August 28, 2024 Industry Updates, Biosimilar Barriers, and & the Impact of IRA Medicare... 6 Minute Read Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.
Market Access Blogs July 29, 2024 The 340B Saga, New Orphan Drug Exclusion Criteria & Drug Shortages... 4 Minute Read Read the latest on IRA implications on rare disease, economic challenges underpinning drug shortages, and navigating the 340B saga.
